Researchers from the University of Trento and collaborators reported a base-editing approach designed to functionally correct the severe cystic fibrosis CFTR 1717-1G>A splicing mutation using optimized SpRY-ABE9 adenine base editing. The work, published in Science Translational Medicine, tested the strategy in patient-derived airway epithelial cells and human cell models. The team reported functional correction with edits detected in up to 30% of target DNA and said off-target activity was minimal. Because the mutation results in little to no CFTR protein production and lacks approved modulator options, the results position base editing as a potential path for patients excluded from current therapies. As with other genome-editing modalities, the next critical questions will center on delivery feasibility and durability of corrected CFTR expression, but the study directly addresses a clinically defined high-need genotype.